Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
Preclinical data for Kura Oncology's next-generation farnesyl transferase inhibitor KO-2806 in combination with cabozantinib has been selected for oral presentation at the 2025 AACR Annual Meeting.
Kura Oncology anticipates topline results from the ziftomenib registration-directed trial for relapsed/refractory NPM1-mutant AML in early 2025.
Kura Oncology is focusing on precision medicines for cancer, targeting genetic mutations to improve treatment efficacy and safety.